Webinars and Commercial Conversations — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Thermo Fisher Scientific
| Company | Thermo Fisher Scientific |
|---|---|
| Name of system | Ion Torrent Genexus Integrated Sequencer; Ion Torrent Genexus Dx Integrated Sequencer |
| City, State | Carlsbad, CA |
| Phone | 800-955-6288 |
| Website | |
| System application/FDA cleared or approved | Genexus: research use; Genexus Dx: in vitro diagnostic and research use/not required |
| Country where designed/Manufactured | U.S./Singapore |
| First year sold in U.S./First year installed in U.S. | Genexus: 2019/2019; Genexus Dx: 2025/2025 |
| System sold internationally | Genexus: yes (worldwide); Genexus Dx: yes (multiple countries) |
| Dimensions of sequencer (H × W × D)/Footprint of sequencer | open: 81.1 × 58.5 × 43.5 in.; closed: 66.1 × 41.9 × 32.1 in./open: 17.67 sq. ft.; closed: 9.36 sq. ft. |
| Accessory equipment supplied with sequencer at no cost | none |
| Type of computer supplied with sequencer | computer for analysis |
| Analysis options provided with sequencer | onboard, cloud based |
| Where library preparation is performed | sequencer |
| Bioinformatics tools provided with sequencer | Ion Torrent Genexus Software (optional: Oncomine Reporter) |
| Sequencer supplied with UPS (uninterruptible power supply) | no |
| Electrical connection required for sequencer | 100–240 VAC |
| List price of entire sequencer and necessary components | — |
| Purchase options | purchase, trade in, lease, reagent rental, finance |
| Warranties offered | first year included with purchase; extended warranty avail. |
| Training included/Total time for basic training per operator | yes/2 days |
| Training location/Follow-up training available | at customer site/yes (extra charge) |
| Maximum No. of samples amplified in a single amplification event | 48 samples on system, 96 samples off instr. (for library prep) |
| Read length/Percent bases >Q30 | up to 400 bp/— |
| Paired-end capability/Tag lengths/Spans | — |
| Fragment/Tag lengths/Spans | — |
| Mate pair/Tag lengths/Spans | — |
| Single end/Tag lengths/Spans | yes/—/up to 400 bp |
| RNA sequencing/Tag lengths/Spans | — |
| ChIP sequencing/Tag lengths/Spans | — |
| Bisulfite sequencing/Tag lengths/Spans | — |
| Maximum No. of reads or fragments sequenced per single-end run | 48–60 million at 200–400 bp (GX5, GX5 Dx); 80–100 million at 200 bp (GX7) |
| Maximum No. of reads or fragments sequenced per paired-end run | — |
| Total No. of nucleotides (bases) sequenced per run | 9.6–12 Gb at 200 bp (GX5, GX5 Dx); 16–20 Gb at 200 bp (GX7) |
| Wet lab bench time for sequencing preparation | 10 minutes |
| Sequencing run time | 19–24 hours (includes automated library prep) |
| Total time for generating standard gDNA library | — |
| • Paired end | — |
| • Fragment | — |
| • Mate pair | — |
| • Single end | — |
| • RNA sequencing | — |
| • Bisulfite sequencing | — |
| • Hands-on time for paired end | — |
| • Hands-on time for fragment | — |
| • Hands-on time for mate pair | — |
| • Hands-on time for single end | — |
| • Hands-on time for RNA sequencing | — |
| • Hands-on time for ChIP sequencing | — |
| • Hands-on time for bisulfite sequencing | — |
| Library preparation integrated in system as standard offering | yes (AmpliSeq, AmpliSeq HD) |
| Cost of sequencing reagents per run | — |
| Reagent tracking method | RFID, barcode reader |
| • Type of reagent information tracked | expiration date, lot and part Nos., placement |
| Shipping conditions for amplification/sequencing reagents | -20°C, 4°C, ambient (variable based on product)/-20°C, 4°C, ambient (variable based on product) |
| Storage conditions for amplification/sequencing reagents | -20°C, 4°C, ambient (variable based on product)/-20°C, 4°C, ambient (variable based on product) |
| Shelf life of amplification/sequencing reagents | 12–36 months from manufacture date (variable based on product)/12–36 months from manufacture date (variable based on product) |
| System requires a control sample on sequencing run | optional |
| • Company offers a sequencing control | yes (additional charge) |
| Sequencing system control software and devices to start run/for data analysis | Ion Torrent Genexus Software/Genexus Software, Oncomine Reporter |
| Complete walkaway automation for amplification, sequencing, and variant calling | yes |
| Remote system monitoring | yes |
| Total time required for setup of amplification, sequencing, and variant calling steps | 10 minutes |
| Maximum No. of libraries sequenced in a single run | 48 samples or 96 libraries |
| System includes secondary data-analysis software developed by company | yes (Ion Reporter, Oncomine Reporter) |
| System includes post-sequencing data-analysis software | yes (Genexus: Genexus Software, Oncomine Reporter;Genexus Dx: Genexus Dx Software, Oncomine Reporter) |
| Mutations detectable via data-analysis software | substitutions, indels, copy number changes, fusions |
| System can generate a variant report | yes |
| Types of maintenance plans available/mean time between failures | AB Assurance, AB Platinum NGS (Dx plans also avail.)/— |
| No. of field application scientists and engineers based in U.S. | 450 |
| • Weekly maintenance required | none |
| • Monthly maintenance required | none |
| • Pre-run maintenance required | none |
| Distinguishing features of NGS system (supplied by company) | Dx sequencer is a CE-IVD-marked, FDA-listed class II IVD medical device; walkaway automation of NGS workflow, incl. library prep, sequencing, analysis, reporting; start with as little as 1 ng of input DNA or RNA; scalable plug-and-play reagent architecture allows for cost-efficient sequencing of small and large batches |